Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
Date:10/10/2007

COLUMBUS, Ohio, Oct. 10 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Tablets, 150mg, 300mg and 600mg by the U.S. Food and Drug Administration. The product is available in bottles of 100 tablets and Unit Dose Blisters for immediate shipment to wholesalers and pharmacies nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO )

Roxane Laboratories' Oxcarbazepine Tablets are AB rated to Trileptal(R) (oxcarbazepine). Annual sales of Oxcarbazepine Tablets 150mg, 300mg and 600mg are approximately $663 Million(1).

Full prescribing information for Oxcarbazepine Tablets is available on the Roxane Laboratories website at http://www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc. is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 05/2007

TRILEPTAL(R) is a registered trademark of Novartis Pharmaceuticals Corporation


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Azathioprine 50mg Pills Recalled By FDA And Roxane Labs
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 21, 2020 , ... The Rise of Mental Health ... a lot of complications and adjustments, needless to say, more complications. With rising deaths, ... the great depression it can be hard to escape and find peace. Adding to ...
(Date:5/17/2020)... ... May 18, 2020 , ... ... therapy program at its Tijuana regenerative clinic. There are two program options for ... safe cell counts. , While it is unclear exactly what causes Autism Spectrum ...
(Date:5/16/2020)... (PRWEB) , ... May 16, 2020 , ... Dr. ... relatively early, this will prevent permanent arthritis from developing. This can keep the foot ... Biernacki further states “It is estimated that the people who develop flat feet and ...
(Date:5/15/2020)... ... May 15, 2020 , ... On May 17, World NF Awareness Day, ... the Heart Is, a benefit to support the Children’s Tumor Foundation and to Make ... to grow on nerves throughout the body and affects all ethnicities, races, and genders ...
(Date:5/14/2020)... ... May 14, 2020 , ... NeoTract, ... in the field of urology, today announced that John Pettit, M.D., Bellingham Urology ... Excellence. The designation recognizes that Dr. Pettit has achieved a high level of ...
Breaking Medicine News(10 mins):
(Date:5/21/2020)... ... May 21, 2020 , ... Sindledecker Dentistry ... offices had been closed due to the coronavirus pandemic and the practice was ... The office has remained open only for emergency needs and the staff, led ...
(Date:5/21/2020)... PASS, Ore. (PRWEB) , ... ... ... 18 May 2020 , Guests: Kevin Kearns, Boston, Massachusetts, founder/CEO of Burn ... for IDEA, the world’s largest association for fitness and wellness professional & ...
(Date:5/17/2020)... NORTH PORT, Fla. (PRWEB) , ... May 17, 2020 , ... ... its immuno-modulatory, anti-fungal, anti-tumor, and other beneficial properties is extracted from the Sea Cucumber ... dose of the active ingredient. , You’ve heard it time and time again: ...
Breaking Medicine Technology: